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Abstract
Objectives. To describe glucocorticoid (GC) use in the SLICC inception cohort and to explore factors
associated with GC use. In particular we aimed to assess temporal trends in GC use and to what extent
physician-related factors may influence use.
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Methods. Patients were recruited within 15 months of diagnosis of SLE from 33 centres between 1999
and 2011 and continue to be reviewed annually. Descriptive statistics were used to detail oral and
parenteral GC use. Cross sectional and longitudinal analyses were performed to explore factors
associated with GC use at enrolment and over time.
Results. We studied 1700 patients with a mean (S.D.) follow-up duration of 7.26 (3.82) years. Over the
entire study period, 1365 (81.3%) patients received oral GCs and 447 (26.3%) received parenteral GCs at
some point. GC use was strongly associated with treatment centre, age, race/ethnicity, sex, disease
duration and disease activity. There was no change in the proportion of patients on GCs or the average
doses of GC used over time according to year of diagnosis.
Conclusion. GCs remain a cornerstone in SLE management and there have been no significant changes
in their use over the past 1015 years. While patient and disease factors contribute to the variation in GC
use, between-centre differences suggest that physician-related factors also contribute. Evidence-based
treatment algorithms are needed to inform a more standardized approach to GC use in SLE.
Key words: systemic lupus erythematosus, glucocorticoids, epidemiology
Rheumatology key messages
. According to year of diagnosis, over 15 years, GC use has not reduced in the SLICC inception cohort.
. Significant variation in GC use exists between treatment centres, even after adjusting for patient factors.
. New therapies and RCTs exploring GC dosing are needed to optimize GC use in SLE.
Introduction
Glucocorticoids (GCs) have been used in the treatment of
SLE for >60 years. Despite their widespread use, there
are only a limited number of small scale clinical trials [13]
and observational studies [49] exploring the most effect-
ive mode, dose or regimen of administration. This limited
evidence, combined with the inherent heterogeneity of the
disease, means than guidelines for the use of GCs in SLE
are not very specific [1016]. As such, there are significant
differences in opinion on the use of GCs in SLE [1719].
Most observational studies describing GC use in SLE are
limited to single centres, small cohorts or SLE disease
subgroups [2023].
A number of factors are likely to influence GC use. These
include patient-related factors (e.g. disease phenotype/se-
verity, comorbidities and personal preference) and patient-
independent factors (e.g. health care setting and opinions of
the treating physician). Two survey-based studies suggest
that prescribing may be more influenced by patient-inde-
pendent factors, such as geographical location [17, 18].
The aims of this study were to describe GC use in detail
in a large international SLE inception cohort and to explore
variations in GC practice between treatment centres.
Finally we aimed to explore what other patient dependent
and independent factors are associated with GC use in
SLE and to determine whether there was any temporal
trend towards more modest GC use over the study period.
Methods
SLICC inception cohort
The Systemic Lupus International Collaborating Clinics
(SLICC) consortium includes 33 centres across North
America, Europe and Asia. Patients were recruited to the
Inception Cohort between 1999 and 2011. All patients
were recruited within 15 months of confirming four ACR
Classification Criteria for SLE [24]. Case report forms
(including demographic, disease, treatment and co-mor-
bidity details) were completed at enrolment and annually
thereafter. Disease activity was quantified using the
SLEDAI-2K [25] and the classic BILAG disease activity
index [26]. Data were submitted to the co-ordinating
centres at the University of Toronto, Toronto, Ontario,
Canada and Dalhousie University, Halifax, Nova Scotia,
Canada. For this analysis, patients with a minimum of
one follow-up assessment (in addition to the enrolment
assessment) were included.
Ethics
The study was approved by the institutional research ethics
boards of participating centres in accordance with the
Declaration of Helsinki’s guidelines for research in humans.
Descriptive analyses of GC use
Information on GC use was recorded at enrolment (past
and current use) and at each annual assessment visit,
including the dose, duration and type of oral (PO) GC
courses. From this data it was possible to calculate the
average daily and total cumulative PO GC doses as well
as the total time/proportion of time spent on PO GCs over
each follow-up interval (FUI; defined as the time from one
assessment to the next). PO doses were transformed into
prednisolone equivalents. The number and dose of paren-
teral GC pulses were also recorded at baseline and at
each follow-up assessment but transformation to prednis-
olone equivalents was not possible, as specific GC
type was not collected for these episodes. Descriptive
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statistics were used to report the proportions of patients
receiving GCs at enrolment (PO and parenteral), the
proportion of FUIs where GC had been given and the
average doses received at enrolment and within FUIs.
Average dose descriptions exclude patients/FUIs where
dose was zero and are reported as median [interquartile
range (IQR)].
Cross-sectional analyses of factors associated with
GC use at enrolment
Potential factors that might influence the use of GCs were
defined a priori from our review of the literature: demo-
graphic details including age, sex and race/ethnicity
(grouped into Caucasian, Asian, Hispanic, African ancestry
and other), disease activity (SLEDAI-2K), disease phenotype
including presence or absence of active renal disease (active
nephritis or any renal manifestation of the SLEDAI-2K). We
also included comorbidities including diabetes mellitus,
hypertension, BMI, concomitant medications (antimalarial
yes/no and/or immunosuppressant yes/no), date of diagno-
sis and treatment centre. Univariable analyses were per-
formed to explore the association between each of these
predictor variables and the following GC outcomes: (1)
taking PO GCs at enrolment (yes/no); (2) average daily
dose of PO GC at enrolment; (3) received parenteral GCs
prior to enrolment (yes/no); and (4) total dose of parenteral
GC received prior to enrolment.
Logistic and linear regression models were used for binary
outcomes (1 and 3) and continuous outcomes (2 and 4—log
transformed data), respectively. For each outcome, predictor
variables significant at univariable analysis (P< 0.20) were
entered into multivariable models using forwards stepwise
selection to create the final models (P< 0.05). Linear regres-
sion results were back transformed and converted to per-
centage dose changes for ease of interpretation. Tests for
interactions between sex and other independent variables
were performed, as was quadratic transformation of BMI
to explore a possible curvilinear relationship with GC use.
To illustrate differences in GC use between centres, we
defined a hypothetical ‘typical’ patient and used the weight-
ings generated by each model to describe the probable GC
use by this ‘typical’ patient at each treatment centre. The
‘typical’ patient was defined (according to the median/
modal values of the predictor variables in the cohort overall)
as a 33-year-old Caucasian female with disease duration of
0.4 years, no active renal disease, hypertension or diabetes,
a SLEDAI2K score of 4 and taking an antimalarial but no
immunosuppressive treatment.
Longitudinal analysis of factors associated with GC
use over time
Random effect modelling was used to explore the rela-
tionship between the same predictor variables (age, sex,
race/ethnicity, diagnosis date and treatment centre were
fixed; all other predictor variables were time-variant) with
the following outcome descriptions of GC use over time:
(1) PO GCs received during preceding FUI (yes/no); (2)
average daily PO GC dose over preceding FUI; (3)
parenteral GCs received during preceding FUI (yes/no);
and (4) total dose of parenteral GC received over preced-
ing FUI.
The GC outcomes were calculated over individual FUIs,
and therefore a patient with an enrolment and three fol-
low-up assessments would contribute data from three
FUIs to the longitudinal analysis.
Outcomes 2 and 4 were again log transformed and final
models were generated through the same process of ini-
tial univariable testing and forwards selection. Quadratic
transformation of BMI was also tested, as were interaction
terms. For descriptions of probable GC use in the hypo-
thetical typical patient, the definition was adapted to a 37
year old female with disease duration of 4.7 years and
SLEDAI2K score of 2, to reflect the median/modal
values of these variables in the cohort over time.
Sensitivity analyses
To further explore the effect of disease activity and pheno-
type, sensitivity analyses were run on all final models: in-
clusion of the BILAG total score; replacement of the total
SLEDAI-2K score with individual components of the score
(selected from arthritis, rash, myositis, serositis, active
neurological disease, thrombocytopenia, low complement
and increased dsDNA binding through univariable testing
(P< 0.20) and forwards stepwise selection (P< 0.05)). We
also examined the influence of body weight on all final
models.
Missing data
Less than 5% of the data was missing for all variables
apart from height, weight and blood pressure. These
were replaced with the average from preceding and sub-
sequent visits or alternatively the preceding or subsequent
visit where possible. Complete case analysis was then
performed, accepting the minimal remaining missing data.
Results
Patients
Of 1848 patients recruited to the SLICC Inception Cohort,
1700 (92%) had a minimum of one follow-up visit and are
included in these analyses. Patient characteristics are
summarized in Table 1. These 1700 patients provided
data on 10 745 FUIs with a mean (S.D.) total time in the
study of 7.26 (3.82) years. The median (IQR) length of
these FUIs was 372 (341427) days.
Descriptive analysis of GC prescription
At enrolment, 1189 (69.98%) patients were taking PO GC
at a median (IQR) daily dose of 20.0 (10.0 30.0) mg; 414
(24.4%) patients were receiving530 mg/day. The propor-
tion of patients receiving PO GC decreased in later FUIs.
For example, by the fifth follow-up assessment, 610/1076
patients (56.90%) had used PO GC over the preceding
FUI, of whom 129 (12.0%) had taken GC for some and
481 (44.7%) for all of the preceding FUI. Similarly the
median (IQR) daily GC dose decreased from 10.0
(5.015.0) mg at follow-up 1 to 5.5 (4.610.0) mg at
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follow-up 5 [mean (S.D.) duration in study at follow-up 1
and 5 = 384 (57) and 1860 (155) days, respectively].
Of the 10732 (99.9%) FUIs in which the proportion of
time on GCs could be calculated, all of the time had been
spent on PO GC in 4946 (46.1%) and none of this time had
been spent on PO GC in 4265 (39.7%); in 1521 (14.2%)
FUIs a proportion of the period had been spent on PO
GCs. Therefore, 558 (32.8%) patients spent their entire
study period on PO GCs, 807 (47.5%) spent part of
the entire study period on PO GC and 335 (19.7%)
never received PO GC therapy (differences in demo-
graphic and disease characteristics of these three
groups can be seen in supplementary Table S1, available
at Rheumatology online).
Regarding parenteral GC, at enrolment 235 (13.8%) pa-
tients had received at least one dose at a median (IQR)
total dose of 1.5 (0.73.0) g. Parenteral GCs were given
between subsequent visits in 458 (4.26%) FUIs at a
median (IQR) total dose of 0.5 (0.122.0) g. Patients who
had parenteral GCs also received a median (IQR) total PO
GC dose of 3.4 (0.56.2) g in the same FUI. Overall more
PO GC was received during those FUIs where higher
doses of parenteral GC were also received (Table 2).
This was also true in the group who had <250 mg of par-
enteral GC, which was likely to have been intra-muscular
and/or intra-articular GCs.
Factors associated with GC use at enrolment and
over time
Treatment centre
There was a significant association between treatment
centre and all four measures of GC use at enrolment
and over time in both univariable (Tables 3 and 4) and
multivariable analyses (P < 0.0001) (Table 5). There were
a number of centres where GC use differed significantly
from the overall cohort, as can be seen in the variability of
average daily PO GC dose between the centres (Table 6).
At enrolment the mean (95% CI) average daily PO GC
dose in the cohort overall was 13.03 (13.0113.06) mg.
The mean dose within individual centres was significantly
different in 25 of the 33 centres with mean average doses
ranging from 4.54 (4.264.83) to 19.84 (17.522.5) mg.
Similar variability was seen in the longitudinal analysis of
PO GC dose and also in all three other GC outcome
measures at enrolment and over time (supplementary
Tables S2 and S3, available at Rheumatology online).
Age, sex and race/ethnicity
We found strong inverse associations between age and
PO GC use in both univariable (Tables 3 and 4) and multi-
variable (Table 5) analyses. Older age was associated with
reduced odds of receiving PO GCs and lower PO GC
dose. For example, in longitudinal analyses the odds of
receiving PO GCs reduced with each additional year of
age (OR = 0.98, 95% CI: 0.96, 0.99) and there was a
small reduction in dose used (% change = 0.66, 95% CI:
0.31, 1.01). There was also a greater odds of men receiv-
ing PO GC (OR = 3.90, 95% CI: 2.19, 6.94) and men also
took higher doses (% change = 16.85, 95% CI: 2.79,
32.83) in longitudinal analysis. When we added body
weight to the final longitudinal models, the dose difference
between men and women was no longer significant (%
change = 13.32, 95% CI: 0.64, 29.24) but men were
still more likely to be taking PO GC steroids (OR = 4.02,
95% CI: 2.24, 7.22). Hispanics, Asians and patients of
African origin all had greater odds of receiving PO GCs
than Caucasians both at enrolment and over time. Race/
ethnicity was also associated with PO GC dose over time,
for example, Hispanics had higher odds of using PO GCs
(OR = 2.46, 95% CI: 0.87, 6.95) and at higher average
doses than Caucasians (% change = 36.07, 95% CI:
TABLE 1 Demographic and baseline disease characteris-
tics of study population
Characteristic (n= 1700 unless
stated otherwise) n (%)/* median (IQR)
Age (n = 1699), years 33.0 (24.543.7)*
Gender
Female 1506 (88.6)
Male 194 (11.4)
Enrolment location
Canada 397 (23.4)
USA 463 (27.2)
Mexico 210 (12.4)
Europe 470 (27.7)
Asia 160 (9.4)
Race/ethnicity
Caucasian 843 (49.6)
Hispanic 262 (15.4)
Asian 254 (14.9)
African origin 278 (16.4)
Other 63 (3.7)
Disease activity/phenotype
SLEDAI-2K (n = 1693) 4 (28)*
SLICC/ACR-Damage Index 51 391 (23.0)
Active renal diseasea 436 (25.7)
Anti-dsDNA positive (n = 1541) 613 (39.8)
Low complement (n = 1548)b 582 (37.6)
Medication use
Oral GC use prior to enrolment
(n = 1699)
1189 (70.0)
Average GC dosec
(n = 1179), mg/day
20.0 (10.030.0)*
Highest GC dosec
(n = 1183), mg/day
40.0 (20.060.0)*
Immunosuppressant use 684 (40.2)
Antimalarial use 1152 (67.8)
Co-morbidities
Hypertension (n = 1683) 758 (45.0)
Diabetes mellitus (n = 1682) 61 (3.6)
Current smoker (n = 1698) 252 (14.8)
Post-menopausal (n = 1506)d 213 (14.1)
BMI, mean (S.D.) (n = 1672), kg/m2 25.7 (5.9)
*Values are in median (IQR). aActive nephritis or any renal
item on SLEDAI-2K (haematuria, proteinuria, pyuria or casts).
bDecrease in CH50, C3 or C4 below the lower limit of normal
for testing laboratory. cAverage/highest GC doses of zero
excluded from calculation. dPercentage of women. IQR,
interquartile range.
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1.65, 82.15). There were no significant associations be-
tween age, sex or race and parenteral GC use (frequency
or dose) either at enrolment or over time, nor did we find
any significant interactions between sex and other inde-
pendent variables.
Other factors
Longer disease duration was associated with lower GC
use by most of the measures used to assess PO and
parenteral use (Table 5). Overall disease activity
(SLEDAI-2K score) was positively associated with the fre-
quency and dose of PO GC and the frequency (but not
dose) of parenteral GC in cross-sectional and longitudinal
analyses. Active renal disease was also associated with
PO GC use (frequency and dose) at enrolment (not over
time) but had no associations with parenteral GC use. We
also found a number of positive associations between
hypertension and diabetes mellitus and GC use but no
associations with BMI. Antimalarial use had a negative
association with a number of GC measures whereas im-
munosuppressant use showed positive associations with
all four measures at enrolment and over time. For example
the OR (95% CI) for receiving parenteral GC at enrolment
if on an antimalarial was 0.63 (0.46, 0.86) and if on an
immunosuppressant was 2.06 (1.52, 2.80). Sensitivity ana-
lyses incorporating BILAG score (supplementary Table
S3, available at Rheumatology online) or significant
SLEDAI 2K components (results available) supported our
primary models.
Diagnosis date
When we examined GC use according to year of diagno-
sis, there were no significant associations between date of
diagnosis and any of the four GC outcomes in either
cross-sectional or longitudinal analysis (Tables 3 and 4).
Discussion
There is growing evidence that lower doses of GCs may
be as effective for the treatment of SLE while incurring
fewer adverse events [69]. As such, a number of review
and guidance articles have advocated more judicious use
of GC [2731]. We have observed that PO GCs were used
frequently in this international SLE cohort with 32.8% of
patients spending their entire observation period on GC
therapy. Also, high doses [32] were commonly used with
24.4% of patients receiving530 mg/day at enrolment. Of
note, we found no association between date of diagnosis
and any of the GC outcomes suggesting that the aspir-
ation for more judicious use has not yet translated into
changes in routine clinical practice over the past 1015
years. It should, however, be noted that in this time
period very few new therapies or therapeutic paradigms
have gained widespread use, but recent results from a
phase III trial of belimumab suggest this may have some
GC-sparing effects [33].
Previous survey-based studies have found geograph-
ical variation in GC use [18] and have found associations
between GC prescribing and physician-related factors
such as specialty and years of experience [17]. We
found significant associations between all four GC meas-
ures and treatment centre at enrolment and over time. A
number of factors are likely to contribute to this between-
centre variability, for example, the local health-care
system (e.g. universal coverage vs insurance-based sys-
tems), socioeconomic status, availability of GC-sparing
agents and cultural acceptance of GC use. Data on
these factors were not collected and therefore they were
absent from our models, but even within countries or
regions (e.g. Canada and Europe), where confounding
from such factors should be less marked, there was still
significant variation in GC use. This real-world variation
between centres requires further exploration but lends
support to the hypothesis that GC use is still driven by
patient-independent factors to a significant degree.
Such patient-independent heterogeneity in GC use will
contribute to ‘noise’ in multicentre clinical trials and will
increase the likelihood of type 2 errors occurring. Our ob-
servations suggest that in such multicentre trials some
TABLE 2 Oral glucocorticoid exposure over follow-up intervals, grouped by total parenteral glucocorticoid dose
received over follow-up interval
Total dose of par-
enteral GC, mga
n (%) of FUI
where PO
GCs have
been used
Median point estimatesb
Total PO GC
dose, mg
Average
daily PO GC
dose, mg
Maximum
daily PO GC
dose, mg
Total time on
PO GC, days
>1000 (n = 182) 172 (94.5) 5503 15.0 30 371
2501000 (n = 90) 80 (88.9) 4663 10.0 30 365
<250 (n = 175) 109 (62.3) 2688 7.5 10 336
0 (n = 10287) 6097 (59.3) 2450 6.0 10 364
P-value for between
group comparisons
<0.001* <0.001** <0.001** <0.001** 0.015**
aInformation on total parenteral GC dose available for 10 734 follow-up intervals. bMedian values calculated from those FUIs
where PO GCs have been used; that is, dose or duration equal to zero not included in the calculation. *Chi-square.
**KruskalWallis. FUI: follow-up interval; GC: glucocorticoid; PO: oral.
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period of standardization of GC use may be necessary to
address such variation prior to randomization. In addition,
international consensus guidelines for GC use in different
clinical situations, for example, LN and arthritis, may go
some way towards reducing the observed variability.
There was significant race/ethnic variation in PO GC
use, with higher use amongst non-Caucasians. Race/eth-
nicity may reflect socioeconomic status at the individual
or population level and PO GC may be a favoured treat-
ment option for uninsured individuals or in poorer coun-
tries due to its relatively low cost. There was also
significantly higher frequency and dosing of GCs in male
patients. Gender differences in the SLE phenotype are
well recognized [34], for example, lower incidence of mus-
culoskeletal features, RP, alopecia and photosensitivity
but more nephritis, serositis and discoid lupus in men.
However, whether men experience higher disease activity,
damage accrual or mortality is more contentious with in-
consistent findings across several studies [3542]. In the
SLICC cohort we found no difference in disease activity
between men and women (data on file) although more
men had active renal disease at enrolment: OR (95% CI)
[age/race adjusted logistic regression] = 1.80 (1.49, 2.90).
Our analyses adjusted for such confounding, but despite
TABLE 3 Univariate analysis of factors associated with oral glucocorticoid use within the SLICC inception cohort
At enrolment Over time
Received PO GCs (yes/no) OR (95% CI) n OR (95% CI) N
Age, years 0.97 (0.96, 0.98) 1698 0.87 (0.85, 0.88) 11 428
Sex, male 1.94 (1.34, 2.83) 1699 5.09 (2.72, 9.51) 11 437
Ethinicity/racea
Hispanic 5.79 (3.90, 8.58) 1699 13.25 (7.63, 23.01) 11 437
Asian 7.71 (4.96, 12.00) 41.38 (23.39, 73.21)
African origin 2.97 (2.16, 4.01) 12.98 (7.49, 22.51)
Other 1.86 (1.07, 3.25) 2.94 (1.06, 8.17)
Diagnosis date 1.00 (1.00, 1.00) 1699 1.00 (1.00, 1.00) 11 437
Disease duration (years) 0.73 (0.54, 0.98) 1699 0.80 (0.78, 0.81) 11 437
Hypertensionb 1.65 (1.33, 2.04) 1683 1.94 (1.62, 2.32) 11 431
Diabetesc 0.88 (0.51, 1.51) 1682 0.79 (0.54, 1.14) 11 437
BMI 0.97 (0.95, 0.99) 1671 0.98 (0.96, 1.00) 11 371
BMI2 1.00 (1.00, 1.00) 1671 1.00 (1.00, 1.00) 11 371
On antimalarial (yes/no) 0.65 (0.52, 0.82) 1699 1.11 (0.91, 1.36) 11 437
On immunosuppressant (yes/no) 8.50 (6.33, 11.41) 1679 8.65 (7.08, 10.58) 11 437
SLEDAI-2K score 1.12 (1.09, 1.15) 1693 1.12 (1.09, 1.14) 11 312
Active renal disease (yes/no) 6.25 (4.40, 8.88) 1699 2.77 (2.15, 3.56) 11 437
Overall treatment centre effect P < 0.0001d 1699 P < 0.0001d 1699
Average daily dose of PO GC (mg) % change (95% CI) n % change (95% CI) N
Age, years 0.89 (1.21, 0.56) 1178 2.13 (2.46, 1.81) 6441
Sex (male) 8.20 (4.80, 22.96) 1179 15.43 (0.46, 32.64) 6450
Ethnicity/racea
Hispanic 47.08 (30.61, 65.62) 41.40 (24.45, 60.65)
Asian 13.19 (0.54, 27.44) 1179 23.00 (8.35, 39.62) 6450
African origin 18.59 (5.03, 33.91) 42.18 (24.90, 61.84)
Other 14.27 (9.60, 44.43) 12.40 (12.66, 44.66)
Diagnosis date 0.003 (0.006, 0.001) 1179 0.00 (0.00, 0.01) 6450
Disease duration (years) 44.12 (50.53, 36.87) 1179 7.29 (7.98, 6.59) 6450
Hypertensionb 32.82 (21.92, 44.70) 1172 20.16 (12.93, 27.85) 6449
Diabetesc 10.41 (29.29, 13.50) 1166 11.54 (1.77, 22.24) 6450
BMI 0.07 (0.70, 0.85) 1161 0.26 (0.39, 0.92) 6414
BMI2 0.00 (0.01, 0.01) 1161 0.00 (0.01, 0.01) 6414
On antimalarial (yes/no) 34.26 (39.82, 28.19) 1177 18.70 (24.30, 12.68) 6450
On immunosuppressant (yes/no) 44.61 (32.89, 57.37) 1177 44.43 (35.44, 54.01) 6450
SLEDAI-2K score 3.85 (3.10, 4.60) 1175 3.40 (2.71, 4.10) 6388
Active renal disease (yes/no) 76.36 (61.81, 92.22) 1179 29.00 (19.56, 39.18) 6450
Overall treatment centre effect P < 0.0001d 1699 P < 0.0001d 1699
aCf. Caucasian. bDefined as systolic blood pressure 5130 mmHg or diastolic blood pressure 590 mmHg or taking anti-
hypertensive medication. cDefined as any past or current history of diabetes. dOverall variation between treatment centres
shown here as P-values for chi-square test. Further detail of between centre differences (in multivariable analyses) shown in
Table 6. n: number of patients; N: number of follow up intervals; PO: oral; GC: glucocorticoid.
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this, a gender difference in GC use persisted. This may
therefore reflect differences due to patient choices or
physicians’ therapeutic strategies in men and women.
For example, men may be less concerned about weight
gain and physicians may have more concerns about
osteoporosis in women. Similarly physicians may hold a
perception that males with SLE require more aggressive
treatment or men may choose to stay on GCs if they are
working in manual occupations.
Our study has some strengths and limitations that are
worth consideration. As far as we are aware, this is the
first time that the use of GCs and factors associated with
their use have been described in a large international SLE
cohort. The large cohort size and long follow-up from early
in the disease course allowed us to adjust for a range of
potential confounders and also explore variations related
to between- and within-centre differences in a real world
setting for several different measures of GC use. We were
limited in not being able to include factors related to
socioeconomic status, as these data were not routinely
collected. As such we recognize that unmeasured con-
founding may account for some of the inter-centre
TABLE 4 Univariate analysis of factors associated with parenteral glucocorticoid use within the SLICC inception cohort
At enrolment Over time
Received parenteral GCs (yes/no) OR (95% CI) n OR (95% CI) N
Age, years 0.99 (0.98, 1.00) 1699 0.98 (0.97, 0.99) 11 468
Sex (male) 1.31 (0.90, 1.90) 1700 1.03 (0.66, 1.59) 11 477
Ethnicity/racea
Hispanic 0.85 (0.55, 1.26) 0.54 (0.35, 0.83)
Asian 1.68 (1.18, 2.38) 1700 0.85 (0.57, 1.28) 11 477
African origin 1.53 (1.08, 2.16) 1.74 (1.21, 2.49)
Other 1.09 (0.54, 2.21) 1.72 (0.88, 3.36)
Diagnosis date 1.00 (1.00, 1.00) 1700 1.00 (1.00, 1.00) 11 477
Disease duration, years 0.88 (0.61, 1.27) 1700 0.87 (0.85, 0.90) 11 477
Hypertensionb 1.89 (1.46, 2.45) 1683 1.50 (1.19, 1.88) 11 471
Diabetesc 1.50 (0.82, 2.77) 1682 2.00 (1.51, 2.63) 11 477
BMI 1.00 (0.98, 1.02) 1672 1.00 (0.98, 1.02) 11 410
BMI2 1.00 (1.00, 1.00) 1672 1.00 (1.00, 1.00) 11 410
On antimalarial (yes/no) 0.56 (0.43, 0.72) 1697 0.78 (0.61, 1.00) 11 477
On immunosuppressant (yes/no) 2.61 (2.01, 3.40) 1697 2.48(1.96, 3.14) 11 477
SLEDAI-2K score 1.06 (1.03, 1.08) 1693 1.08 (1.06, 1.11) 11 347
Active renal disease (yes/no) 1.84 (1.40, 2.41) 1700 1.32 (1.00, 1.75) 11 477
Overall treatment centre effect P < 0.0001d 1699 P < 0.0001d 1699
Total dose of GC, mg % change (95% CI) n % change (95% CI) N
Age, years 1.45 (2.79, 0.09) 235 2.74 (3.87, 1.59) 549
Sex (male) 64.13 (1.30, 172.92) 235 40.21 (12.74, 125.28) 550
Ethnicity/racea
Hispanic 217.33 (77.91, 466.03) 185.31 (75.40, 364.10)
Asian 25.29 (23.11, 104.13) 36.32 (12.18, 111.61) 550
African origin 51.70 (5.92, 144.60) 235 42.30 (2.67, 108.06)
Other 4.30 (62.03, 186.46) 138.40 (21.23, 368.83)
Diagnosis date 0.01 (0.02, 0.01) 235 0.01 (0.02, 0.01) 550
Disease duration, years 6.20 (38.28, 82.71) 235 10.80 (14.02, 7.47) 550
Hypertensionb 68.70 (15.72, 145.97) 233 38.02 (5.40, 80.72) 549
Diabetesc 18.03 (64.55, 89.54) 235 30.01 (4.61, 61.58) 396
BMI 1.74 (4.49, 1.09) 233 0.90 (3.06, 1.32) 548
BMI2 0.02 (0.07, 0.02) 233 0.01 (0.04, 0.03) 548
On antimalarial (yes/no) 45.73 (62.19, 22.10) 235 42.13 (56.37, 23.23) 550
On immunosuppressant (yes/no) 194.01 (104.83, 322.02) 235 276.02 (192.45, 383.48) 550
SLEDAI-2K score 2.03 (0.65, 4.79) 235 3.72 (0.98, 6.53) 545
Active renal disease (yes/no) 103.63 (40.98, 194.12) 235 124.68 (66.55, 203.10) 550
Overall treatment centre effect P < 0.0001d 1699 P < 0.0001d 1699
aCf. Caucasians. bDefined as systolic blood pressure 5130 mmHg or diastolic blood pressure 590 mmHg or taking anti-
hypertensive medication. cDefined as any past or current history of diabetes. dOverall variation between treatment centres
shown here as P-values for chi-square test. Further detail of between centre differences (in multivariable analyses) shown in
Table 6. n: number of patients; N: number of follow up intervals; GC: glucocorticoid.
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variation observed. No data were collected on the specific
formulation of parenteral GCs and we were therefore
unable to calculate a standardized dose. Although we
recognize that some parenteral doses will not have bioe-
quivalence, it is likely that a significant majority of the par-
enteral GCs used will be methylprednisolone or
triamcinolone, which are bioequivalent, minimizing the
impact of this limitation. Another major strength is the
low level of missing data in the cohort although we also
recognize that the annual data collection may introduce
some recall bias on the part of the patient and physician
when completing details of steroid courses.
We have therefore found significant between-centre
variation across a range of different measures of GC use
TABLE 5 Significant factors associated with glucocorticoid use in the SLICC Inception Cohort in final multivariable models
At enrolment Over time
Oral
On GCs (yes/no) OR (95% CI) OR (95% CI)
Age, years 0.99 (0.98, 1.00) 0.98 (0.96, 0.99)
Sex (male) 2.35 (1.47, 3.74) 3.90 (2.19, 6.94)
Ethnicity/racea
Hispanic 2.16 (1.05, 4.45) 2.46 (0.87, 6.95)*
Asian 3.28 (1.77, 6.09) 3.73 (1.74, 7.98)
African origin 2.42 (1.62, 3.61) 4.65 (2.68, 8.08)
Other 1.56 (0.81, 3.02) 2.20 (0.89, 5.42)*
Disease duration, years 0.48 (0.32, 0.72) 0.81 (0.79, 0.83)
Hypertensionb — 1.89 (1.56, 2.30)
On immunosuppressant (yes/no) 7.07 (5.04, 9.92) 8.72 (7.03, 10.83)
SLEDAI-2K 1.08 (1.04, 1.12) 1.09 (1.06, 1.12)
Active renal disease (yes/no) 1.85 (1.16, 2.94) —
Overall treatment centre effect P < 0.0001d P < 0.0001d
Daily GC dose, mg % difference (95% CI) % difference (95% CI)
Age, years 0.72 (1.02, 0.42) 0.66 (1.01, 0.31)
Sex (male) — 16.85 (2.79, 32.83)
Ethnicity/racea
Hispanic — 36.07 (1.65, 82.15)
Asian — 3.63 (20.51, 16.82)*
African origin — 15.80 (1.06, 32.68)
Other — 1.59 (19.74, 28.59)*
Disease duration, years 42.95 (49.02, 36.16) 6.63 (7.39, 5.87)
Hypertensionb 18.76 (9.55, 28.73) 20.90 (13.77, 28.46)
Diabetesc — 10.02 (1.01, 19.82)
On antimalarial (yes/no) 21.47 (27.72, 14.67) 13.28 (19.08, 7.07)
On immunosuppressant (yes/no) 28.05 (18.42, 38.46) 36.00 (27.75, 44.79)
SLEDAI-2K 0.84 (0.04, 1.65) 2.25 (1.58, 2.93)
Active renal disease (yes/no) 22.42 (10.83, 35.23) —
Overall treatment centre effect P < 0.0001d P < 0.0001d
Parenteral
Received GC (yes/no) OR (95% CI) OR (95% CI)
Disease duration (years) — 0.88 (0.86, 0.91)
Hypertensionb 1.53 (1.13, 2.07) 1.41 (1.13, 1.76)
Diabetesc — 1.45 (1.13, 1.86)
On antimalarial (yes/no) 0.63 (0.46, 0.86) —
On immunosuppressant (yes/no) 2.06 (1.52, 2.80) 12.18 (1.73, 2.76)
SLEDAI-2K 1.06 (1.04, 1.09) 1.09 (1.07, 1.12)
Overall treatment centre effect P < 0.0001d P < 0.0001d
Total dose, mg % difference (95% CI) % difference (95% CI)
Disease duration (years) — 9.35 (12.27, 6.34)
On antimalarial (yes/no) 36.26 (55,96, 7.76) —
On immunosuppressant (yes/no) 94.61 (33.81, 183.06) 158.98 (102.39, 231.39)
Overall treatment centre effect P < 0.0001d P < 0.0001
aCf. Caucasians. bDefined as systolic blood pressure 5130 mmHg or diastolic blood pressure 590 mmHg or taking anti-
hypertensive medication. cDefined as any past or current history of diabetes. dOverall variation between treatment centres
shown here as P-values for chi-square test. Further detail of between centre differences shown in Table 6. *Non-significant.
GC: glucocorticoid.
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in SLE patients. Several patient-related factors such as
age, gender, race/ethnicity, disease activity and renal in-
volvement explain part of this variation; however, our
models suggest that physician-dependent factors still
have a major influence in determining GC use. We also
found no major change in GC use over the past 15 years
and so current standard of care remains dependent on
GC use. New therapies will be needed to provide better,
GC sparing/avoiding approaches to SLE management.
Taken together, the challenge now will be to develop
better evidence-based treatment algorithms to optimize
GC use, reduce variation and minimize GC harm in SLE.
Such an approach will also likely contribute to a more
consistent ‘standard of care’ and thus improve the likeli-
hood of success in future clinical trials.
Supplementary data
Supplementary data are available at Rheumatology online.
TABLE 6 Average mean daily oral GC dose of hypothetical typical patient at each treatment centre at enrolment and
over time
Treatment centre
Mean average daily PO GC dose at
enrolment, mg (95% CI)
Mean average daily PO GC dose
between assessments, mg (95% CI)
Cohort overall 13.03 (13.01, 13.06) 3.64 (3.63, 3.66)
USA
1 13.10 (12.81,13.39) 3.59 (3.45, 3.74)
2 14.60 (11.42, 18.68) 6.18 (3.73, 10.24)
3 17.72 (17.38, 18.68) 4.49 (4.34, 4.65)
4 10.05 (9.71, 10.40) 2.54 (2.39, 2.69)
5 NAa 6.81 (0.71, 65.67)
6 13.30 (12.65, 13.99) 2.62 (2.46, 2.79)
7 11.75 (11.42, 12.08) 2.88 (2.78, 2.98)
8 17.76 (17.06, 18.49) 4.06 (3.84, 4.29)
9 13.44 (13.21, 13.67) 3.61 (3.50, 3.73)
10 7.22 (7.00, 7.46) 2.06 (1.96, 2.16)
11 13.78 (13.24, 14.33) 3.05 (2.87, 3.24)
12 19.52 (18.57, 20.51) 5.27 (4.77, 5.82)
13 14.98 (12.92, 17.38) 2.52 (1.71, 3.72)
Europe
14 13.34 (12.68, 14.04) 4.16 (3.67, 4.73)
15 17.65 (15.86, 19.64) 4.87 (4.06, 5.83)
16 8.02 (7.75, 8.30) 3.42 (3.22, 3.63)
17 7.91 (7.80, 8.03) 3.99 (3.92, 4.07)
18 9.31 (8.95, 9.68) 3.33 (3.18, 3.49)
19 10.59 (10.15, 11.06) 3.03 (2.88, 3.19)
20 12.12 (11.33, 12.95) 3.51 (3.18, 3.88)
21 19.84 (17.50, 22.50) 1.66 (1.10, 2.51)
22 11.89 (11.17, 12.65) 4.15 (3.82, 4.50)
23 10.40 (10.11, 10.70) 3.14 (3.03, 3.25)
24 15.50 (10.77, 22.31) 3.69 (2.40, 5.67)
25 4.54 (4.26, 4.83) 1.80 (1.61, 2.01)
26 5.21 (3.61, 7.52) 4.47 (3.88, 5.15)
27 11.77 (11.66, 11.88) 4.36 (4.31, 4.42)
Canada
28 16.00 (15.84, 16.17) 2.54 (2.50, 2.59)
29 18.46 (18.32, 18.61) 4.59 (4.53, 4.65)
30 16.27 (15.99, 16.56) 1.90 (1.85, 1.95)
31 12.21 (8.46, 17.64) 3.73 (1.76, 7.93)
Other
32 14.59 (14.50, 14.68) 3.59 (3.55, 3.62)
33 11.53 (11.46, 11.60) 3.88 (3.83, 3.92)
For the cross sectional analysis of PO GC dose at enrolment, a typical patient is defined as a 33-year-old Caucasian female
with disease duration of 0.4 years, no active renal disease, hypertension or diabetes, SELDAI2K score of 4 and taking an
antimalarial but no immunosuppressive treatment. For the longitudinal analysis of PO GC dose over time, a typical patient is
defined as a 37-year-old Caucasian female with disease duration of 4.7 years, no active renal disease, hypertension or
diabetes, a SELDAI2K score of 2 and taking an antimalarial but no immunosuppressive treatment. Results in bold show
where GC use at a centre differs significantly from the cohort overall (i.e. the confidence intervals do not overlap). aNo data
(only one patient receiving PO GC in this centre, for whom no dose data available). GC: glucocorticoid.
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